Drug Database
Back to search

Belgium· BE-AMP-SAM179006-00

Somatuline Prolonged Release 30 mg

A lanreotide product containing lanreotide acetate, registered in Belgium by Ipsen. The same ATC class is registered in 17 of our 19 countries.

ATC H01CB03

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedSomatuline Prolonged Release 30 mgATCH01CB03REGISTER NO.BE-AMP-SAM179006-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lanreotide acetateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lanreotide is registered in 17 of 19 countries.

Countries holding a registration under ATC H01CB03 (lanreotide), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 10 of them publish a price we can compare per daily dose
Search lanreotide products by name

Lanreotide · ATC H01CB03

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lanreotide costs, country by country.

Normalised to the WHO defined daily dose (3 mg), so markets compare like for like.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Lanreotide · price per daily dose (3 mg)

USD · FX 28 Sept 2026

  • FR France$53.80
  • CH Switzerland$44.46
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Lanreotide Acetate
Manufacturer
Ipsen
Country
Belgium (BE)
ATC code
H01CB03
ATC class
Lanreotide
Defined daily dose
3 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    1375112
  • be_apb
    0761080

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

157 interactions on record for lanreotide.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check lanreotide against other medicinesHow interaction checks work

Lanreotide · interactions on record

157 records

  • 2 severe
  • 151 moderate
  • 4 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • PexidartinibL01EX15severe
  • LiraglutidA08AX02moderate
  • SemaglutidA08AX03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lanreotide in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lanreotide products

Authorised across Europe · EMA

The same active substance is authorised in 5 EEA countries. Names it is sold under:

  • France · Myrelez L.P.
  • United Kingdom (Northern Ireland) · Lanreotide Sun
  • Hungary · Mytolac
  • Netherlands · Mytolac
  • Poland · Lanreotide Ranbaxy

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ac36d844-7835-42d8-9dfe-33dd6b261964
GET /v1/drugs/ac36d844-7835-42d8-9dfe-33dd6b261964?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder and solvent for prolonged-release suspension for injection",
  "source": "afmps",
  "status": "REVOKED",
  "name_en": "Somatuline Prolonged Release 30 mg",
  "name_fr": "Somatuline Prolonged Release 30 mg",
  "name_nl": "Somatuline Prolonged Release 30 mg",
  "amp_code": "SAM179006-00",
  "strengths": [
    "30.0000",
    "30.0000",
    "16.0000",
    "85.0000",
    "0.2000"
  ],
  "pack_count": 3,
  "substances": [
    "Lanreotide Acetate",
    "Lanreotide",
    "Mannitol",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Lanreotide",
  "authorisation_numbers": [
    "BE179006"
  ]
}
API referenceMCP serverPlans

See everything about lanreotide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console